Mutations in DNA damage repair pathway genes, including BRCA2 and CHEK2 have also been reported in pancreatic NET48 and may promote tumour sensitivity to LuTate, as reported in BRCA2 mutant prostate cancer treated with Lu-177 PSMA therapy49. This evidence concerns the gene BRCA2 and prostate carcinoma.